Clinical Trial Detail

NCT ID NCT03149029
Title Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

melanoma

Therapies

Dabrafenib + Pembrolizumab + Trametinib

Pembrolizumab + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST